HomeBRNS • NASDAQ
Barinthus Biotherapeutics PLC - ADR
add
Market news
NDAQ
0.63%
0.00%
Financials
Income Statement
Revenue
Net Income
Revenue
Net income
(USD) | Mar 2025info | Y/Y change |
---|---|---|
Revenue | — | — |
Operating expense | 12.64M | 118.55% |
Net income | -19.65M | -26.85% |
Net profit margin | — | — |
Earnings per share | -0.49 | -22.50% |
EBITDA | -19.36M | -21.86% |
Effective tax rate | 0.11% | — |
Balance Sheet
Total Assets
Total Liabilities
Total assets
Total liabilities
(USD) | Mar 2025info | Y/Y change |
---|---|---|
Cash and short-term investments | 99.12M | -23.74% |
Total assets | 142.00M | -28.82% |
Total liabilities | 26.40M | -3.87% |
Total equity | 115.59M | — |
Shares outstanding | 40.34M | — |
Price to book | 0.32 | — |
Return on assets | -34.07% | — |
Return on capital | -38.19% | — |
Cash Flow
Net Change in Cash
Net change in cash
(USD) | Mar 2025info | Y/Y change |
---|---|---|
Net income | -19.65M | -26.85% |
Cash from operations | -14.90M | -26.05% |
Cash from investing | -5.00K | 98.38% |
Cash from financing | 2.00K | -99.60% |
Net change in cash | -11.82M | 2.46% |
Free cash flow | -9.79M | -67.99% |
Previous close
$0.91
Day range
$0.91 - $1.00
Year range
$0.64 - $1.58
Market cap
40.39M USD
Avg Volume
31.42K
Primary exchange
NASDAQ
About
Barinthus Biotherapeutics plc is a biotechnology company developing immunotherapies for infectious diseases, cancer and autoimmune diseases such as hepatitis B, HPV and prostate cancer. Formerly known as Vaccitech plc, in November 2023 the company announced that it had renamed itself to Barinthus Biotherapeutics plc. As of 2024, the company employs more than 100 people. Wikipedia
Founded
2016
Website
Employees
105